Photodynamic therapy update.
Photodynamic therapy uses a photoactivating agent to selectively treat choroidal neovascularization. In April 2000, the United States Food and Drug Administration approved verteporfin photodynamic therapy for the treatment of subfoveal, predominately classic, choroidal neovascularization caused by age-related macular degeneration. The treatment of choroidal neovascularization from other causes such as myopia, angioid streaks, and idiopathy, and presumed ocular histoplasmosis syndrome is still under investigation. Other photoactivating agents are being evaluated. Photodynamic therapy has been shown to halt the progression of visual loss in patients with age-related macular degeneration who have subfoveal predominately classic choroidal neovascularization. The socio-economic impact of verteporfin approval has yet to be determined.
Shuler
M F
MF
Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Borrillo
J L
JL
Ho
A C
AC
D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D006801:Humans; D008268:Macular Degeneration / Q000150:complications; D008665:Metalloporphyrins / Q000627:therapeutic use; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000191:economics / Q000627:therapeutic use*; D011166:Porphyrins / Q000191:economics / Q000627:therapeutic use*; D000077362:Verteporfin
D008665:Metalloporphyrins; D017319:Photosensitizing Agents; D011166:Porphyrins; C102825:motexafin lutetium; D000077362:Verteporfin; C063166:tin etiopurpurin; C437683:motexafin gadolinium